Sanofi’s Blueprint Medicines presents data on Ayvakit ay AAAAI

Blueprint Medicines, a Sanofi (SNY) company, announced Ayvakit data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent systemic mastocytosis. Key presentations include four-year Pioneer clinical study results highlighting sustained symptom control and quality of life improvement in Ayvakit-treated patients, and real-world data showing meaningful symptom benefit in patients receiving the therapy in a community practice setting. In addition, a study conducted with the Advanced Practitioner Society for Hematology and Oncology, APSHO, and The Mast Cell Disease Society, TMS, reinforces the severe symptoms and impaired quality of life experienced by patients with ISM. In total, 12 data presentations are being reported at the 2026 American Academy of Allergy, Asthma and Immunology, AAAAI, Annual Meeting, February 27 – March 2 in Philadelphia.